Prospects for correcting endothelial dysfunction with high doses of L-arginine in the prevention of cardiorenal complications: a focus on diabetes mellitus
Background. The current concept of cardiorenal metabolic syndrome involves the search for a single therapeutic target of intervention, specifically the functional state of the endothelium. Special attention is given to patients with diabetes mellitus (DM), who face the highest risks. The aim of the study was to analyze the literature data regarding endothelial function in type 2 DM and the role of high doses of L-arginine as a potential therapeutic requirement. Materials and methods. A literature search was conducted in the following databases: MEDLINE/PubMed, Web of Science, Scopus, Cochrane Library, and Google Scholar, encompassing studies published up to June 2026. The search was performed using the keywords: “L-arginine”, “cardiorenal metabolic syndrome”, “diabetes mellitus”, “efficacy”, “safety”. Results. Endothelial dysfunction (ED) is a well-known risk factor for the development of cardiovascular and cerebrovascular diseases, as well as diabetic nephropathy. Evaluating high doses of L-arginine as the sole endogenous substrate for ED correction represents a promising direction. Complex bioregulatory mechanisms (cofactor deficiency, decreased expression of NO synthase (NOS), or an excess of endogenous NOS inhibitors) necessitate discussion regarding the most effective doses of L-arginine in patients with diabetes mellitus and cardiorenal metabolic syndrome. Study results demonstrate significant improvements in ED, insulin secretion and sensitivity, glucose tolerance, a reduction in inflammation, and a positive effect on lipid metabolism. Conclusions. ED is one of the key mechanisms driving the progression of cardiorenal complications in DM. The use of exogenous L-arginine possesses pathogenetically sound therapeutic potential, with high-dose therapy in the range of 6 to 12 g/day being clinically expedient — providing adequate substrate supply for the NO synthesis and matching the dosage range demonstrated as effective in clinical trials.
Authors
- M.M.M. Grechanyk (ORCID: https://orcid.org/0000-0003-2191-3194)
- Olexandr V. Kuryata (ORCID: https://orcid.org/0000-0001-7642-0077)
Institutions
- Dnipro State Medical University (UA)
Publication Details
- Journal
- INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Published
- 2026-11-14
- DOI
- https://doi.org/10.22141/2224-0721.22.7.2026.1774
- Primary Topic
- Nitric Oxide and Endothelin Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00